Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Plos One
|
March 26, 2013
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
Fabien Reyal, David Hajage, Alexia Savignoni, et al.
Breast Cancer Research : BCR
|
November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
William Jacot, Paul Cottu, Frederique Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Breast Cancer Research and Treatment
|
August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Breast Cancer (Tokyo, Japan)
|
January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
Breast (Edinburgh, Scotland)
|
August 23, 2025
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives
Leonor Matos, Mette van Ramshorst, Volkmar Müller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Plos One
|
March 26, 2013
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
Fabien Reyal, David Hajage, Alexia Savignoni, et al.
Breast Cancer Research : BCR
|
November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
William Jacot, Paul Cottu, Frederique Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Breast Cancer Research and Treatment
|
August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
Breast Cancer (Tokyo, Japan)
|
January 11, 2023
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, et al.
Breast (Edinburgh, Scotland)
|
August 23, 2025
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives
Leonor Matos, Mette van Ramshorst, Volkmar Müller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Page
of 3